Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
Identifieur interne : 004780 ( PubMed/Curation ); précédent : 004779; suivant : 004781Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
Auteurs : F. Picard [France] ; A. De Saint-Martin ; E. Salmon ; E. Hirsch ; C. MarescauxSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1996.
English descriptors
- KwdEn :
- Adult, Bromocriptine (administration & dosage), Bromocriptine (therapeutic use), Dopamine Agonists (administration & dosage), Dopamine Agonists (therapeutic use), Drug Therapy, Combination, Encephalitis (complications), Encephalitis (physiopathology), Humans, Levodopa (administration & dosage), Levodopa (pharmacology), Levodopa (therapeutic use), Magnetic Resonance Imaging, Male, Parkinson Disease, Secondary (complications), Parkinson Disease, Secondary (drug therapy), Putamen (physiopathology), Receptors, Dopamine D2 (drug effects), Stereotyped Behavior, Tomography, X-Ray Computed, Trihexyphenidyl (administration & dosage), Trihexyphenidyl (therapeutic use).
- MESH :
- chemical , administration & dosage : Bromocriptine, Dopamine Agonists, Levodopa, Trihexyphenidyl.
- chemical , drug effects : Receptors, Dopamine D2.
- chemical , pharmacology : Levodopa.
- chemical , therapeutic use : Bromocriptine, Dopamine Agonists, Levodopa, Trihexyphenidyl.
- complications : Encephalitis, Parkinson Disease, Secondary.
- drug therapy : Parkinson Disease, Secondary.
- physiopathology : Encephalitis, Putamen.
- Adult, Drug Therapy, Combination, Humans, Magnetic Resonance Imaging, Male, Stereotyped Behavior, Tomography, X-Ray Computed.
Abstract
In 1954, at the age of 5 years, our patient had an encephalitic syndrome associated with a prolonged lethargic state. After this episode, he developed a severe parkinsonian syndrome that, after a few years, was associated with axial dystonia and stereotyped abnormal movements of the upper limbs. This complex and progressive extrapyramidal syndrome had many similarities to the encephalitis lethargica as described by von Economo. Results of cerebral computed tomography and magnetic resonance imaging were normal. Fluorodopa positron emission tomography showed a significant bilateral reduction of tracer accumulation in both putamen, similar to that observed in patients with idiopathic Parkinson's disease. However, in this patient, treatment with L-Dopa suppressed all akinetic, dystonic and dyskinetic symptoms. The effectiveness of L-Dopa was abolished by administration of a D2 antagonist and was fully reproduced by a D2 agonist. In conclusion, this patient presented a complex postencephalitic, extrapyramidal syndrome, with akinetic symptoms and involuntary movements. These symptoms appeared to be related to a limited lesion of the dopaminergic neurons of the zona compacta of the substantia nigra.
DOI: 10.1002/mds.870110513
PubMed: 8866499
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004780
Links to Exploration step
pubmed:8866499Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Postencephalitic stereotyped involuntary movements responsive to L-Dopa.</title><author><name sortKey="Picard, F" sort="Picard, F" uniqKey="Picard F" first="F" last="Picard">F. Picard</name><affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hopitaux Universitaires de Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hopitaux Universitaires de Strasbourg</wicri:regionArea></affiliation></author><author><name sortKey="De Saint Martin, A" sort="De Saint Martin, A" uniqKey="De Saint Martin A" first="A" last="De Saint-Martin">A. De Saint-Martin</name></author><author><name sortKey="Salmon, E" sort="Salmon, E" uniqKey="Salmon E" first="E" last="Salmon">E. Salmon</name></author><author><name sortKey="Hirsch, E" sort="Hirsch, E" uniqKey="Hirsch E" first="E" last="Hirsch">E. Hirsch</name></author><author><name sortKey="Marescaux, C" sort="Marescaux, C" uniqKey="Marescaux C" first="C" last="Marescaux">C. Marescaux</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1996">1996</date><idno type="RBID">pubmed:8866499</idno><idno type="pmid">8866499</idno><idno type="doi">10.1002/mds.870110513</idno><idno type="wicri:Area/PubMed/Corpus">004780</idno><idno type="wicri:Area/PubMed/Curation">004780</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Postencephalitic stereotyped involuntary movements responsive to L-Dopa.</title><author><name sortKey="Picard, F" sort="Picard, F" uniqKey="Picard F" first="F" last="Picard">F. Picard</name><affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hopitaux Universitaires de Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hopitaux Universitaires de Strasbourg</wicri:regionArea></affiliation></author><author><name sortKey="De Saint Martin, A" sort="De Saint Martin, A" uniqKey="De Saint Martin A" first="A" last="De Saint-Martin">A. De Saint-Martin</name></author><author><name sortKey="Salmon, E" sort="Salmon, E" uniqKey="Salmon E" first="E" last="Salmon">E. Salmon</name></author><author><name sortKey="Hirsch, E" sort="Hirsch, E" uniqKey="Hirsch E" first="E" last="Hirsch">E. Hirsch</name></author><author><name sortKey="Marescaux, C" sort="Marescaux, C" uniqKey="Marescaux C" first="C" last="Marescaux">C. Marescaux</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1996" type="published">1996</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Bromocriptine (administration & dosage)</term><term>Bromocriptine (therapeutic use)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Encephalitis (complications)</term><term>Encephalitis (physiopathology)</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Parkinson Disease, Secondary (complications)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Putamen (physiopathology)</term><term>Receptors, Dopamine D2 (drug effects)</term><term>Stereotyped Behavior</term><term>Tomography, X-Ray Computed</term><term>Trihexyphenidyl (administration & dosage)</term><term>Trihexyphenidyl (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Trihexyphenidyl</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Trihexyphenidyl</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Encephalitis</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Encephalitis</term><term>Putamen</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Stereotyped Behavior</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In 1954, at the age of 5 years, our patient had an encephalitic syndrome associated with a prolonged lethargic state. After this episode, he developed a severe parkinsonian syndrome that, after a few years, was associated with axial dystonia and stereotyped abnormal movements of the upper limbs. This complex and progressive extrapyramidal syndrome had many similarities to the encephalitis lethargica as described by von Economo. Results of cerebral computed tomography and magnetic resonance imaging were normal. Fluorodopa positron emission tomography showed a significant bilateral reduction of tracer accumulation in both putamen, similar to that observed in patients with idiopathic Parkinson's disease. However, in this patient, treatment with L-Dopa suppressed all akinetic, dystonic and dyskinetic symptoms. The effectiveness of L-Dopa was abolished by administration of a D2 antagonist and was fully reproduced by a D2 agonist. In conclusion, this patient presented a complex postencephalitic, extrapyramidal syndrome, with akinetic symptoms and involuntary movements. These symptoms appeared to be related to a limited lesion of the dopaminergic neurons of the zona compacta of the substantia nigra.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8866499</PMID><DateCreated><Year>1997</Year><Month>01</Month><Day>10</Day></DateCreated><DateCompleted><Year>1997</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>1996</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Postencephalitic stereotyped involuntary movements responsive to L-Dopa.</ArticleTitle><Pagination><MedlinePgn>567-70</MedlinePgn></Pagination><Abstract><AbstractText>In 1954, at the age of 5 years, our patient had an encephalitic syndrome associated with a prolonged lethargic state. After this episode, he developed a severe parkinsonian syndrome that, after a few years, was associated with axial dystonia and stereotyped abnormal movements of the upper limbs. This complex and progressive extrapyramidal syndrome had many similarities to the encephalitis lethargica as described by von Economo. Results of cerebral computed tomography and magnetic resonance imaging were normal. Fluorodopa positron emission tomography showed a significant bilateral reduction of tracer accumulation in both putamen, similar to that observed in patients with idiopathic Parkinson's disease. However, in this patient, treatment with L-Dopa suppressed all akinetic, dystonic and dyskinetic symptoms. The effectiveness of L-Dopa was abolished by administration of a D2 antagonist and was fully reproduced by a D2 agonist. In conclusion, this patient presented a complex postencephalitic, extrapyramidal syndrome, with akinetic symptoms and involuntary movements. These symptoms appeared to be related to a limited lesion of the dopaminergic neurons of the zona compacta of the substantia nigra.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Picard</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de Neurologie, Neuropsychologie et Explorations Fonctionnelles des Epilepsies, Hopitaux Universitaires de Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Saint-Martin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Marescaux</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber><NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>6RC5V8B7PO</RegistryNumber><NameOfSubstance UI="D014282">Trihexyphenidyl</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001971">Bromocriptine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004660">Encephalitis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011699">Putamen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D013239">Stereotyped Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014282">Trihexyphenidyl</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8866499</ArticleId><ArticleId IdType="doi">10.1002/mds.870110513</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004780 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004780 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:8866499
|texte= Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8866499" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |